Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PSE-free products

This article was originally published in The Tan Sheet

Executive Summary

Sine-Off is the "first and only brand" of cough, cold, flu and sinus medicine to "completely remove pseudoephedrine from all of its products - not only nasal decongestants," Hogil Pharmaceutical announces Dec. 7. The line, which is now reformulated with phenylephrine, includes Sinus & Cold, Multi-Symptomand Sinus Painand iscurrently available in major mass retailers and drugstores nationwide. In addition, Hogil and its Sine-Off Charitable Foundation will provide an unrestricted educational grant to the Partnership for a Drug-Free America to support anti-meth measures, the firm announces. The firm will donate a percentage of sales from Sine-Off products to local anti-drug charities as well...

You may also be interested in...



Sine-Off Claims To Fight Cough, Cold, Flu – And Meth Abuse

Ads for reformulated Sine-Off cold and sinus products are scripted to position the brand as an active contributor to the nation's fight against methamphetamine abuse

P&G Begins US Price Increases In Baby And Feminine Care, Could Expand To Health, Beauty

P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.

Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.

Topics

UsernamePublicRestriction

Register

PS098923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel